Source author record

Yunjian Yin

Yunjian Yin appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
3topics
3close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2016arXiv

Assessing the Treatment Effect Heterogeneity with a Latent Variable

The average treatment effect (ATE) is popularly used to assess the treatment effect. However, the ATE implicitly assumes a homogenous treatment effect even amongst individuals with different characteristics. In this paper, we mainly focus on assessing the treatment effect heterogeneity, which has important implications in designing the optimal individual treatment regimens and in policy making. The treatment benefit rate (TBR) and treatment harm rate (THR) have been defined to characterize the magnitude of heterogeneity for binary outcomes. When the outcomes are continuous, we extend the definitions of the TBR and THR to compare the difference between potential outcomes with a pre-specified level c. Unlike the ATE, these rates involve the joint distribution of the potential outcomes and can not be identified without further assumptions even in randomized clinical trials. In this article, we assume the potential outcomes are independent conditional on the observed covariates and an unmeasured latent variable. Under this assumption, we prove the identification of the TBR and THR in non-separable (generalized) linear models for both continuous and binary outcomes. We then propose estimators and derive their asymptotic distributions. In the simulation studies, we implement our proposed methods to assess the performance of our estimators and carry out a sensitive analysis for different underlying distribution for the latent variable. Finally, we illustrate the proposed methods in two randomized controlled trials.

preprint2016arXiv

Novel Criteria to Exclude the Surrogate Paradox and Their Optimalities

When the primary outcome is hard to collect, surrogate endpoint is typically used as a substitute. However, even when the treatment has a positive average causal effect (ACE) on the surrogate endpoint, which also has a positive ACE on the primary outcome, it is still possible that the treatment has a negative ACE on the primary outcome. Such a phenomenon is called the surrogate paradox and greatly challenges the use of surrogate. In this paper, we provide novel criteria to exclude the surrogate paradox. Unlike other conditions previously proposed, our conditions are testable since they only involve observed data. Furthermore, our criteria are optimal in the sense that they are sufficient and "almost necessary" to exclude the paradox: if the conditions are satisfied, the surrogate paradox is guaranteed to be absent while if the conditions fail, there exists a data generating process with surrogate paradox that can generate the same observed data. That is, our criteria capture all the information in the observed data to exclude the surrogate paradox rather than relying on unverifiable distributional assumptions.